If peptides are the body's messages, receptors are the mailboxes. Understanding that relationship explains almost everything about why peptide drugs are dosed the way they are, and why some effects fade fast while others last for days.

Signaling: A Lock-and-Key System

A peptide hormone travels through the bloodstream or extracellular fluid until it reaches a cell with a matching receptor, a protein embedded in or on the cell membrane. When the peptide binds, it changes the receptor's shape, which triggers a chain of chemical events inside the cell. This is how GLP-1 receptor agonists like semaglutide slow gastric emptying and signal the brain's appetite centers, and how growth hormone secretagogues like CJC-1295 prompt the pituitary gland to release more growth hormone.

Selectivity Matters

Some peptides bind tightly to one receptor type and almost nothing else, which researchers call selectivity. Others bind more broadly, which can mean more effects but also more side effects. Ipamorelin, for instance, is often studied because it appears more selective for the growth hormone pathway than older secretagogues, which historically also triggered cortisol and prolactin release.

Why Half-Life Determines Dosing

Half-life is the time it takes for half of a dose to be cleared from the body. Natural GLP-1 has a half-life of just a couple of minutes, which is why the native hormone can't be used as a drug. Semaglutide's half-life is about a week, achieved through chemical modifications that resist the enzymes that normally break peptides down and bind the molecule to albumin in the blood. That's the entire reason it can be injected weekly instead of constantly.

Shorter-acting peptides, including many growth hormone secretagogues, have half-lives measured in minutes to a few hours, which is why protocols for those compounds often involve more frequent dosing, when they're used at all in supervised clinical settings.

Enzymes Are the Limiting Factor

The main reason most peptides can't simply be swallowed as a pill is enzymatic degradation. Stomach acid and digestive enzymes are extremely good at breaking peptide bonds, which is exactly what they evolved to do with dietary protein. That's why most peptide therapies are injectable, and why oral peptide formulations require special chemistry to survive the gut, like the absorption enhancer used in oral semaglutide (Rybelsus).

Why This Matters for Evaluating Claims

When you see a peptide marketed with a specific dosing schedule, the underlying pharmacology, receptor selectivity, and half-life should back that schedule up. A compound with a poorly characterized half-life and no controlled human dosing studies can't responsibly be given a precise "optimal protocol," no matter how confidently it's marketed. That gap between established pharmacology and marketing claims is one of the most useful things to watch for across this entire category.

Downregulation and Tolerance

Receptors aren't static. Cells exposed to persistently high levels of a signaling molecule often respond by reducing the number of active receptors on their surface, a process called downregulation, which can blunt a peptide's effect over time. This is one reason growth hormone secretagogue protocols are sometimes designed around pulsatile rather than constant stimulation, attempting to mimic the body's natural, rhythmic release pattern rather than a steady, unbroken signal. It's also a reminder that a peptide's effect at week one isn't necessarily a reliable guide to its effect at month six.